Showing 1831-1840 of 2123 results for "".
- McDonald Criteria Updates for MS Diagnosis Announcedhttps://practicalneurology.com/news/mcdonald-criteria-updates-for-ms-diagnosis-announced/2470587/Proposed revisions to the 2017 McDonald diagnostic criteria for multiple sclerosis (MS) were announced at the 40th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The updates, which will be published later this year, provide guidance on the use of im
- Long-Term Data Reveal Ocrevus Comparable to Tysabri Tx in Effectiveness, Safety Outcomeshttps://practicalneurology.com/news/long-term-data-reveals-ocrevus-comparable-to-tysabri-tx-in-effectiveness-safety-outcomes/2470583/Treatment with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) for people with multiple sclerosis (MS) showed comparable effectiveness, safety, and treatment persistence to treatment with Tysabri (natalizumab; Biogen, Cambridge, MA) over a 5-year observation period. The results of a lon
- Promising Results for mAb Migraine Treatment Targeting PACAP Reported in NEJMhttps://practicalneurology.com/news/promising-results-for-mab-migraine-treatment-targeting-pacap-reported-in-nejm/2470582/A single intravenous infusion of Lu AG09222 (Lundbeck, Deerfield, IL), a humanized monoclonal antibody (mAb) that targets the pituitary adenylate cyclase-activating polypeptide (PACAP) ligand, was found to be superior to placebo in reducing migraine frequency over 4 weeks. The results of a phase
- Wearable Chest Sleep Apnea Test Receives FDA Clearancehttps://practicalneurology.com/news/wearable-chest-sleep-apnea-test-receives-fda-clearance/2470557/The Food and Drug Administration (FDA) has granted 510(k) clearance to SANSA (Huxley Medical, Atlanta, GA), a sleep apnea patch that is worn on the chest. SANSA is an at-home, single-point-of-contact diagnostic device that does not require additional attachments such as belts, wires, or hoses. Th
- Intranasal Foralumab Receives Fast Track Designation as Potential Tx for Non-Active SPMShttps://practicalneurology.com/news/intranasal-foralumab-receives-fast-track-designation-as-potential-tx-for-non-active-spms/2470554/An intranasal formulation for foralumab (Tiziana Life Sciences, New York, NY) has been granted Fast Track Designation by the Food and Drug Administration (FDA) for investigation as a potential treatment for non-active Secondary Progressive Multiple Sclerosis (na-SPMS). Foralumab is a fully human
- Once-Daily Pill Approved to Treat Forms of Astrocytoma and Oligodendrogliomahttps://practicalneurology.com/news/once-daily-pill-approved-to-treat-forms-of-astrocytoma-and-oligodendroglioma/2470553/The Food and Drug Administration (FDA) has approved Voranigo (vorasidenib; Servier, Boston, MA) for the treatment of adults and children aged ≥12 years with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutati
- Promising Results for Novel Sigma-1 Receptor Therapy as Alzheimer Treatmenthttps://practicalneurology.com/news/novel-sigma-1-receptor-therapy-slowed-clinical-progression-in-alzheimer-disease/2470543/Treatment with Anavex2-73 (blarcamesine; Anavex Life Sciences, New York, NY) for people with early Alzheimer disease (AD) was associated with slowed clinical progression in cognitive and functional outcomes. Anavex2-73 is a small-molecule activator of the sigma-1 receptor (SIGMAR1) that is orally
- Experimental Combo Treatment Reduced Alzheimer Disease-Associated Agitationhttps://practicalneurology.com/news/experimental-combo-treatment-reduced-alzheimer-disease-associated-agitation/2470535/Results of the ACCORD (NCT04797715) clinical trial presented at the 2024 meeting of the Alzheimer’s Association International Conference (AAIC) demonstrated that AXS-05 (dextromethorphan-bupropion; Axsome Therapeutics, New York, NY) treatment reduced agitation symptom relapse and was well-t
- Investigational Intradiscal Injection Improved Pain Associated with Lumbar Disc Herniationhttps://practicalneurology.com/news/investigational-intradiscal-injection-improved-pain-associated-with-lumbar-disc-herniation/2470528/People treated with experimental product SI-6603 (condoliase; Ferring Pharmaceuticals, Parsippany, NJ; Seikagaku, Tokyo, Japan) by a single intradiscal injection showed improvements in the radicular leg pain associated with their lumbar disc herniation (LDH). Early response data from a phase 3 st
- CMS Launches New Program to Support People with Dementia and their Caregivershttps://practicalneurology.com/news/cms-launches-new-program-to-support-people-with-dementia-and-their-caregivers/2470526/On July 1, 2024, the Centers for Medicare & Medicaid Services (CMS) announced the launch of the Guiding an Improved Dementia Experience (GUIDE) Model, a voluntary nationwide model test designed to support people with dementia and their caregivers. The GUIDE Model will be active for 8 years an